Skip to main content
Home
  • Twitter
  • Facebook
  • YouTube
  • Instagram
  • Blog
  • Contact
  • de
animals Animals
climate Climate Crisis
Conflict Regions
Culture
Democracy
Development & Aid
Economy
Education
energy Energy
environment Environment
Exemplary People
food Food & Agriculture
Globalization
Health
Human Rights
Men
military Military
nature Nature
News Media
nuclear weapons Nuclear Disarmament
Peace
Politics
Religions
Social Justice
Sustainability
Women
Youth
Useful Tools
Real News
Events

Vaccinations

  1. Home
  2. Health
  3. Info by Disease
  4. Infections
  5. Novel Coronavirus Guide
  6. Scientific Papers
Suggest a link
Cancel
  • * HELP ! - Expert help urgently needed. Please email us links on relevant papers.268633
  • Covid-19: Focus should be on new vaccines rather than boosters, says WHO - BMJ 17.01.22271563
  • Covid-19: Fourth vaccine doses—who needs them and why? - BMJ 07.01.22269874
  • Covid-19: Whatever happened to the Novavax vaccine? - BMJ 08.12.21265301
  • Covid-19: Antibody boost after third dose varies greatly by vaccine, study finds - BMJ 03.12.21265300
  • Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis - MedRxiv 2021270356
  • Covid-19: GPs need extra staff and capacity to deliver accelerated booster programme, say leaders - BMJ 02.12.21265299
  • Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentr…265171
  • ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome - Science 01.12.21264277
  • Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland - Science Direct 13.11.21263111
  • Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet 29.10.21261587
  • COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021 - CDC 29.10.21270602
  • Journal: Covid-19 breakthrough infections in vaccinated health care workers - NEJM 14.10.21263636
  • Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study - BMJ 27.08.21257823
  • Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection - MedRxiv 19.08.21256172
  • Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III) - THe Lancet 01.06.21247429
  • “Vaccine-Induced Covid-19 Mimicry” Syndrome: Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic e…245947
  • Scientists zero in on long-sought marker of COVID-vaccine efficacy - nature 21.05.21245703
  • Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women - JAMA 13.05.21245533
  • Racial/Ethnic Disparities In COVID-19 Exposure Risk, Testing, And Cases At The Subcounty Level In California - HealthAffairs 12.05.21244861
  • Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged ≥65 Years - CDC 11.05.21247430
  • Vaccination plus Decarceration — Stopping Covid-19 in Jails and Prisons - NEJM 29.04.21247431
  • COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN) - The Lancet 23.04.21247434
  • Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - Lancet 23.04.21247432
  • Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination - JAMA 23.04.21247433
  • SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women - JAMA 12.04.21247435
  • Human rights and fair access to COVID-19 vaccines: the International AIDS Society - Lancet 24.03.21247436
  • Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center - NEJM 23.03.21247437
  • Covid-19 vaccine shortages: what is the cause and what are the implications? - BMJ 19.03.21247438
  • Covid-19: What do we know about Sputnik V and other Russian vaccines? - BMJ 19.03.21247439
  • Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study - Lancet 18.03.21247440
  • Covid-19: Chile joins top five countries in world vaccination league - BMJ 17.03.21247441
  • Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients - JAMA 15.03.21247442
  • SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans - Research Square 10.03.21247443
  • Acute Allergic Reactions to mRNA COVID-19 Vaccines - JAMA 08.03.21244333
  • COVID-19 vaccine response in pregnant and lactating women: a cohort study - BMJ 07.03.21247444
  • Should spreading anti-vaccine misinformation be criminalised? - BMJ 17.02.21247445
  • Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19 - Association of Anaesthetists 11.02.21244357
  • Vaccines are curbing COVID: Data from Israel show drop in infections - nature 05.02.21247446
  • How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis - HealthAffairs 04.02.21244365
  • Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine - MedRxiv 01.02.21247447
  • COVID-19 : Critical Vaccine Distribution, Supply Chain, Program Integrity, and Other Challenges Require Focused Federal Attention - Gao 28.01.21247448
  • Why vaccinating staff and supporting self-isolating people are national emergencies - BMJ 28.01.21244410
  • Covid-19 vaccination: What’s the evidence for extending the dosing interval? - BMJ 06.01.21247449
  • Covid-19: Vaccine brands can be mixed in “extremely rare occasions,” says Public Health England - BMJ 04.01.21247450
  • Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination - Harvard Edu 2021244408
  • ** Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine - NEJM 31.12.20247451
  • ** Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine - NEJM 30.12.20247452
  • A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 - medrxiv 11.12.20247453
  • * Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 - The Lancet 08.12.20247454
  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) - The Lancet 18.11.20247455
  • Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years - The Lancet 17.11.20247456
  • Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations - NJEM 16.10.20247457
  • Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers (BBV152) - NIH 01.10.20247458
  • The global economic cost of COVID-19 vaccine nationalism - RAND 10/20247459
  • “When Will We Have a Vaccine?” — Understanding Questions and Answers about Covid-19 Vaccination - NEJM 08.09.20247460
  • Immunological considerations for COVID-19 vaccine strategies - Nature Review Immunology 04.09.20247461
  • India will supply coronavirus vaccines to the world — will its people benefit? - nature 03.09.20247462
  • Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine - NEJM 02.09.20247463
  • Nationalisme vaccinal à l’ère de la Covid-19 : Un frein à l’endiguement de la pandémie - Policy Center for the New South 02.09.20268507
  • COVID-19 vaccines and neglected pregnancy - Lancet 27.08.20247464
  • China’s coronavirus vaccines are leaping ahead – but face challenges as virus wanes - nature 31.07.20247465
  • Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques - Nature 20.07.20247466
  • Development of an inactivated vaccine candidate for SARS-CoV-2 - Science 06.05.20244700
  • COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges - Lancet 04.05.20247467
  • Considering BCG vaccination to reduce the impact of COVID-19 - Lancet 30.04.20244701
  • The race for coronavirus vaccines: a graphical guide - Nature 28.04.20244703
  • SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction - Nature Research 23.04.20244704
  • The COVID-19 vaccine development landscape - Nature's Review 09.04.20244707
  • If a coronavirus vaccine arrives, can the world make enough? - nature 09.04.20244706
  • News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine - PNAS 30.03.20244710
  • Should scientists infect healthy people with the coronavirus to test vaccines? - nature 26.03.20244712
  • Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19 - medRxiv 24.03.20247468
  • Estimating the effect of cooperative versus uncooperative strategies of COVID-19 vaccine allocation: a modeling study - Chinazza, Mu et al247470
  • About Us
    • FAQ
    • Endorsements
    • Privacy Policy
    • Disclaimer
    • Publisher
    • Press
  • Get Involved
    • What can I do?
    • Add a Link
    • Share knowledge
    • Donate
    • Contact us

Follow us

  • Twitter
  • Facebook
  • YouTube
  • Instagram
to top

share

Privacy
Details
Imprint | Privacy
Your selection from
The controller (Dr. Norbert Stute, Austria) would like to use the following services in order to process your personal data. Technologies such as cookies, localStorage, etc. can be used for personalization. This is not necessary for the use of the website, but allows us to interact with you more closely. If you wish, you can adjust or revoke your consent at any time via our privacy policy.
Other content (1 Service)
Integration of additional information
Switch to accept or reject the category Other content

X (Twitter)
Twitter International Unlimited Company, Ireland
All Detailsto X (Twitter)
All Detailsto X (Twitter)
Switch to accept or reject the service X (Twitter)
When accessing some sub-services of our website, additional personal services are processed. Processed data categories: technical connection data of the server access (IP address, date, time, requested page, browser information)data about the use of the website and the logging of clicks on individual elements. Purpose of processing: Selection of online advertising on other platforms, which are automatically selected using real-time bidding based on user behavior and provision of social media services. The legal basis for processing: Your consent according to Art. 6 (1) a GDPR. Data is transmitted: as joint controllers for Twitter International Unlimited Company, One Cumberland Place, Fenian Street Dublin 2, D02 AX07, Ireland. This may also mean a transfer of personal data to a country outside the European Union. The data is transmitted on the basis of your consent in accordance with Art. 6 Para. 1 lit a in conjunction with Art. 49 Para. 1 lit a GDPR. You were informed before you gave your consent that the USA does not have a level of data protection that corresponds to the standards of the EU. In particular, US secret services can access your data without you being informed and without you being able to take legal action against it.
Switch to accept or reject the service